The CROWN Phase IIIb result is a clinically meaningful step-change for Cabenuva, but the evidence package remains incomplete in ways that matter for both regulators and payers. [1] Meeting a superiority endpoint — not merely non-inferiority — against standard-of-care oral ART in approximately 326 treatment-experienced, virologically unsuppressed adults and adolescents is a qualitatively stronger claim than the non-inferiority maintenance data that underpinned every prior Cabenuva approval (ATLAS, FLAIR, ATLAS-2M — all Phase 3 RCTs in suppressed patients). [1] The clinical logic is coherent: patients with detectable virus are, by definition, those for whom daily oral adherence has failed, making the directly observed, every-two-month injectable format most relevant precisely here. [2][3] The LATITUDE study is cited as the prior foundation, but its full data are not publicly available, preventing independent verification of what CROWN was designed to confirm or extend. No precedent in the available evidence base clears both the mechanistic-fit bar (INSTI + NNRTI long-acting injectable) and the full clinical-context bar (treatment-experienced, virologically unsuppressed population) simultaneously — the closest verified precedents are the suppressed-patient pivotal trials, which differ on the critical population dimension. Across multiple HTA jurisdictions, prior Cabenuva assessments yielded 'no added value' (Danish Medicines Council, 2022), 'additional benefit not proven' (G-BA, 2021), 'ASMR V' (HAS), and cost-minimisation-only recommendation (PBAC, November 2021) — all in the easier suppressed population. A superiority claim in a harder population could shift those verdicts, but only if the full dataset resolves the three critical unknowns: the resistance profile of enrolled patients (rilpivirine's low genetic barrier is a documented vulnerability in treatment-experienced patients), the magnitude of the superiority margin, and durability beyond the six-month primary endpoint. The open-label design introduces a structural adherence asymmetry — patients randomised to injectable therapy are relieved of the daily pill burden that caused their viremia, which may inflate the apparent superiority independently of pharmacological effect. The sharpest risk is that resistance emergence data, when reported, reveal a pattern consistent with the existing evidence showing resistance mutations in the majority of virological failures on this combination. [4]
CROWN (Phase 3b RCT, ~326 participants) met its six-month superiority primary endpoint, but no suppression rates, confidence intervals, resistance data, or durability data beyond six months are reported; the open-label design introduces an adherence-asymmetry confound specific to this viremic population. [1]
| Indication | HIV-1 infection |
| Drug | cabotegravir and rilpivirine |
| Mechanism of Action | INSTI and NNRTI |
| Company | ViiV Healthcare |
| Trial Phase | Phase IIIb |
| Trial Acronym | CROWN |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Positive |
| Therapeutic Area | Infectious Diseases & Vaccines |
| Primary Endpoint | superior rates of viral suppression |
| Patient Population | adults and adolescents living with HIV-1 who had detectable virus when they entered the study, with a history of antiretroviral treatment and unsuppressed HIV, no evidence of resistance to INSTIs or NNRTIs |
| Comparator | standard-of-care oral antiretroviral therapy (ART) |
| Dosage Frequency | six times a year |
| Primary Endpoint Timepoint | six months |
| Number of Participants | approximately 326 |
| Study Design | international, randomised, open-label |
| Approved Markets (Cabenuva) | US, EU, Japan, other markets |
| ViiV Healthcare Shareholders | GSK, Shionogi |
| Rilpivirine Developer | Johnson & Johnson |
ViiV Healthcare's Cabenuva Achieves Superior Viral Suppression in Viremic HIV Patients
ViiV Healthcare, majority-owned by GSK, announced that its long-acting HIV treatment, Cabenuva (cabotegravir and rilpivirine), met its primary endpoint in the Phase IIIb CROWN study. The trial demonstrated superior rates of viral suppression at six months compared to standard-of-care oral antiretroviral therapy in adults and adolescents living with HIV-1 who had detectable virus at study entry. This international, randomised, open-label study enrolled approximately 326 participants and addresses an evidence gap by evaluating direct initiation of Cabenuva in treatment-experienced individuals with unsuppressed HIV, building on previous findings from the LATITUDE study.
- The CROWN study is a Phase IIIb international, randomised, open-label trial that enrolled approximately 326 adults and adolescents across eight countries. It specifically investigated the investigational use of long-acting Cabenuva in people with a history of antiretroviral treatment and unsuppressed HIV-1 (detectable virus at study entry), who had no evidence of resistance to INSTIs or NNRTIs.
- The CROWN study builds upon the LATITUDE study, which showed Cabenuva's superiority in maintaining viral suppression in already suppressed patients with adherence challenges. CROWN uniquely evaluates direct initiation of Cabenuva in patients who still had detectable virus, providing crucial insights into its potential role for treatment-experienced individuals struggling to achieve or maintain viral suppression.
- Cabenuva (cabotegravir and rilpivirine) is currently approved in the US, EU, Japan, and other markets for HIV-1 infection in virologically suppressed adults and adolescents. Cabotegravir is an integrase strand transfer inhibitor (INSTI), preventing viral DNA integration, while rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI), interfering with reverse transcriptase to stop viral multiplication.
CROWN Study Design and Its Breakthrough in Viremic HIV-1
Multiple pivotal phase 2 and phase 3 trials have evaluated a range of antiretroviral regimens across treatment-naive, virologically suppressed, and treatment-experienced HIV-1 populations. The studies span integrase inhibitor-, protease inhibitor-, NNRTI-, and capsid inhibitor-based strategies, with most employing the FDA Snapshot algorithm at week 48 as the primary efficacy endpoint.
| Trial / Study | Phase | Design | Population | Primary Endpoint | Non-Inferiority Margin | Key Comparators |
|---|---|---|---|---|---|---|
| WRHI 052 | 3 | Randomised, open-label, parallel-group | Virologically suppressed adults (HIV-1 RNA <50 copies/mL) on LPV/r ≥6 months | Proportion with HIV-1 RNA <50 copies/mL at week 48 (FDA Snapshot) | −4% | DRV 400 mg + RTV 100 mg QD vs. LPV/r (800/200 mg) |
| ACTG A5353 | 2 | Single-arm, pilot | Treatment-naive adults, HIV-1 RNA ≥1,000 and <500,000 copies/mL | Proportion with HIV-1 RNA <50 copies/mL at week 24 (FDA Snapshot) | Not applicable (single arm) | DTG 50 mg + 3TC 300 mg QD |
| NCT02345226 (EFV→RPV/FTC/TAF switch) | 3b | Randomised, double-blind, placebo-controlled | Virologically suppressed adults on EFV/FTC/TDF ≥6 months | Proportion with HIV-1 RNA <50 copies/mL at week 48 (FDA Snapshot) | 8% | RPV/FTC/TAF vs. EFV/FTC/TDF |
| NCT01815736 (RPV/FTC/TDF→RPV/FTC/TAF switch) | 3b | Randomised, double-blind, placebo-controlled | Virologically suppressed adults on RPV/FTC/TDF ≥6 months | Proportion with HIV-1 RNA <50 copies/mL at week 48 (FDA Snapshot) | 8% | RPV/FTC/TAF vs. RPV/FTC/TDF |
| DAWNING | 3b | Open-label, parallel-group, active-controlled | Adults with virological failure on first-line NNRTI + 2 NRTIs | Proportion with HIV-1 RNA <50 copies/mL at week 48 (Snapshot) | −12% | DTG 50 mg QD + 2 NRTIs vs. LPV/r + 2 NRTIs |
| GS-US-380-1490 | 3 | Randomised, double-blind, placebo-controlled | Treatment-naive adults (HIV-1 RNA ≥500 copies/mL) | Proportion with HIV-1 RNA <50 copies/mL at week 48 (FDA Snapshot) | −12% | BIC/FTC/TAF vs. DTG + FTC/TAF |
| GS-US-380-1489 | 3 | Randomised, double-blind, active-controlled | Treatment-naive adults (HIV-1 RNA ≥500 copies/mL), HLA-B*5701-negative | Proportion with HIV-1 RNA <50 copies/mL at week 48 (FDA Snapshot) | −12% | BIC/FTC/TAF vs. DTG/ABC/3TC |
| BIC/FTC/TAF vs. DTG/ABC/3TC (week 96) | 3 | Randomised, double-blind, active-controlled | Treatment-naive adults | Proportion with HIV-1 RNA <50 copies/mL at week 96 (FDA Snapshot) | −12% | BIC/FTC/TAF vs. DTG/ABC/3TC |
| BIC/FTC/TAF vs. DTG + FTC/TAF (week 96) | 3 | Randomised, double-blind, active-controlled | Treatment-naive adults | Proportion with HIV-1 RNA <50 copies/mL at week 96 (FDA Snapshot) | −12% | BIC/FTC/TAF vs. DTG + FTC/TAF |
| BIC/FTC/TAF switch from boosted PI | 3 | Randomised, open-label, active-controlled | Virologically suppressed adults on boosted ATV or DRV + FTC/TDF or ABC/3TC | Proportion with HIV-1 RNA ≥50 copies/mL at week 48 (FDA Snapshot) | 4% | BIC/FTC/TAF vs. continued boosted PI regimen |
| NCT02121795 (FTC/TDF→FTC/TAF switch) | 3 | Randomised, double-blind, active-controlled | Virologically suppressed adults on FTC/TDF-containing regimens | Proportion with HIV-1 RNA <50 copies/mL at week 48 (FDA Snapshot) | 10% | FTC/TAF vs. FTC/TDF (same third agent) |
| TAF/FTC vs. ABC/3TC | 3 | Randomised, double-blind, active-controlled | Virologically suppressed adults on ABC/3TC-containing regimens | Proportion with HIV-1 RNA <50 copies/mL at week 48 (Snapshot) | 10% | TAF/FTC vs. ABC/3TC (same third drug) |
| SPRINT | 3 | Randomised, double-blind, active-controlled | Virologically suppressed adults on NNRTI-based ART ≥12 months | Proportion with HIV-1 RNA ≥50 copies/mL at week 48 (FDA Snapshot) | 4 percentage points | ANV/3TC/TDF vs. EVG/Cobi/FTC/TAF |
| CARES | 3 | Randomised, open-label | Virologically suppressed adults (HIV-1 RNA <50 copies/mL), no history of virological failure | Proportion with HIV-1 RNA <50 copies/mL at week 48 (FDA Snapshot) | 10 percentage points | CAB 600 mg + RPV 900 mg IM every 8 weeks vs. continued oral ART |
| ATLAS + FLAIR (pooled) | 3 | Randomised, open-label, multicenter | Virologically suppressed adults (HIV-1 RNA <50 copies/mL) | Proportion with HIV-1 RNA ≥50 copies/mL at week 48 (FDA Snapshot) | 4% | CAB + RPV LA monthly injections vs. continued oral ART |
| ATLAS-2M | 3b | Randomised, open-label, active-controlled | Treatment-experienced adults, virologically suppressed | Proportion with HIV-1 RNA ≥50 copies/mL at week 48 (Snapshot) | 4% | CAB + RPV LA every 8 weeks vs. every 4 weeks |
| GEMINI-1 & GEMINI-2 (week 144) | 3 | Randomised, double-blind (through week 96) | Treatment-naive adults, HIV-1 RNA ≤500,000 copies/mL, no major resistance mutations | Proportion with HIV-1 RNA <50 copies/mL at week 144 (Snapshot) | Not reported for week 144 secondary analysis | DTG + 3TC vs. DTG + TDF/FTC |
| D2ARLING | 4 | Randomised, open-label, single-centre | Treatment-naive adults, no baseline resistance testing available | Proportion with HIV-1 RNA <50 copies/mL at week 48 (Snapshot, ITT-E) | 10% | DTG 50 mg + 3TC 300 mg vs. DTG + TDF/FTC or TDF/3TC (3-drug) |
| SWORD-1 & SWORD-2 (week 148) | 3 | Open-label, randomised (1:1) | Virologically suppressed adults (HIV-1 RNA <50 copies/mL ≥6 months), no prior virological failure | Proportion with HIV-1 RNA <50 copies/mL at week 148 (Snapshot) | Not reported for week 148 | DTG + RPV (early switch) vs. continued ART then switch at week 52 |
| FLAMINGO | 3b | Randomised, open-label, multicentre | Treatment-naive adults (HIV-1 RNA ≥1,000 copies/mL), no resistance at screening | Proportion with HIV-1 RNA <50 copies/mL at week 48 (FDA Snapshot) | 12% | DTG 50 mg QD vs. DRV + RTV 800/100 mg QD + investigator-selected NRTIs |
| PROTEA (week 96) | Randomised controlled | Randomised controlled | Virologically suppressed adults (HIV-1 RNA <50 copies/mL) on first-line ART | Proportion with HIV-1 RNA <50 copies/mL at week 96 (FDA Snapshot) | Not reported | DRV/r 800/100 mg QD monotherapy vs. DRV/r + 2 NRTIs |
| DOMONO | 2 | Randomised, open-label, non-inferiority | Virologically suppressed adults (HIV RNA <50 copies/mL ≥6 months), CD4 nadir ≥200 cells/μL | Proportion with HIV-1 RNA <200 copies/mL at week 24 | 12% | DTG 50 mg QD monotherapy (immediate vs. delayed switch) |
| WAVES | 3 | Randomised, double-blind, active-controlled | Treatment-naive HIV-infected women | Proportion with HIV-1 RNA <50 copies/mL at week 48 (FDA Snapshot) | 12% | EVG/COBI/FTC/TDF vs. ATV + RTV + FTC/TDF |
| ANRS 12 300 Reflate TB 2 | 3 | Randomised, open-label, non-inferiority | ART-naive adults co-infected with HIV-1 and tuberculosis on rifampicin | Proportion with HIV-1 RNA <50 copies/mL at week 48 | 12% | RAL 400 mg BID vs. EFV 600 mg QD, both + TDF + 3TC |
| NCT04223778 (DOR/ISL switch) | 3 | Randomised, open-label, active-controlled | Virologically suppressed adults (<50 HIV-1 RNA copies/mL) on any oral 2- or 3-drug ART ≥3 months, no prior virological failure | Proportion with HIV-1 RNA ≥50 copies/mL at week 48 (FDA Snapshot) | 4% | DOR 100 mg + ISL 0·75 mg QD vs. continued baseline ART |
| ARTISTRY-1 (Phase 2, week 48 & week 96) | 2/3 | Randomised (2:2:1), operationally seamless | Virologically suppressed adults (HIV-1 RNA <50 copies/mL) on complex ART, no known INSTI resistance | Virologic suppression at week 48; resistance analysis through week 96 | Not reported | BIC + LEN (75 mg + 25 mg or 75 mg + 50 mg) vs. stable background regimen; extension to BIC/LEN 75/50 mg STR |
| NCT02582684 (RPV switch, Rwanda) | Not reported | Randomised, open-label, non-inferiority | Virologically suppressed HIV-1-infected Rwandan adults on nevirapine + 2 NRTIs | Proportion with HIV-1 RNA <200 copies/mL at week 24 (FDA Snapshot) | 12% | RPV/FTC/TDF vs. continued NVP-based ART |
Addressing Unmet Needs for Treatment-Experienced Viremic HIV-1 Patients
The HIV-1 treatment landscape continues to evolve, with clinical research increasingly focused on populations and clinical scenarios where standard antiretroviral regimens fall short. Several distinct unmet needs have emerged as priority areas across recent literature.
Heavily treatment-experienced (HTE) adults with multidrug-resistant HIV-1 remain a critical population with limited therapeutic options. Agents such as fostemsavir, ibalizumab, and lenacapavir have been evaluated specifically in this group. In the phase 3 BRIGHTE trial, 53% of participants had no more than one fully active antiretroviral drug at baseline, underscoring the severity of resistance burden in this cohort. Real-world French data confirmed that PWH receiving fostemsavir or ibalizumab harbored resistance to 94–96% of NRTI and NNRTI classes, with genotypic susceptibility scores ≤1 in 47% of fostemsavir-treated patients.
Adherence-challenged populations, including those unable to sustain daily oral regimens, represent a major unmet need driving development of long-acting injectable (LAI) formulations. Real-world data on LAI cabotegravir/rilpivirine in patients with high comorbidity burdens and adherence issues demonstrated an overall discontinuation probability of 14.9% at week 52, with younger age protective against discontinuation. Pharmacogenomic variability — including CYP2B6, CYP2C19, and CYP3A5 variants — has been identified as a potential contributor to virologic abnormalities in adolescents and young adults receiving LAI cabotegravir/rilpivirine, representing an understudied mechanistic gap.
Pediatric and adolescent populations with perinatally acquired HIV-1 face a dual burden: limited treatment options historically and an emerging cardiometabolic comorbidity risk from early, prolonged HIV-1 and ART exposure. Contemporary ART regimens show improved cardiometabolic profiles versus older regimens, yet well-designed studies in this population remain insufficient. Timely identification and treatment of HIV-infected newborns and children also remains operationally challenging despite evidence that early ART initiation reduces HIV-1 reservoir size.
Racially and ethnically underrepresented groups — specifically Black and Hispanic/Latine adults — are disproportionately affected by HIV-1 and have historically been underrepresented in clinical trials. Five-year data from studies 1489 and 1490 showed that Black people with HIV were more likely than non-Black people to have low adherence (<85%) (11% vs. 5%; p = 0.0074), highlighting adherence as a population-specific unmet need even within efficacious regimens.
People with HIV and high cumulative viremia represent a population at elevated multimorbidity risk. Among ART-treated women with HIV, those with time-updated cumulative viremia copy-years ≥7 log copy-years/mL had an adjusted hazard ratio of multimorbidity of 3.78 (95% CI, 2.17–6.58) compared with those with <5 log copy-years/mL, identifying cumulative viremia as a prognostically relevant biomarker for non-AIDS comorbidity risk assessment.
Prevention gaps, particularly adherence to daily oral PrEP, continue to drive development of long-acting prophylactic strategies. In June 2025, the FDA approved lenacapavir for PrEP, and emerging strategies under development include annual lenacapavir formulations, broadly neutralizing antibodies, and the dapivirine vaginal ring, which has demonstrated greater convenience and improved adherence among pregnant women compared to oral PrEP.
Cabenuva's Role in the Evolving Long-Acting HIV-1 Treatment Landscape
The HIV-1 treatment landscape has undergone substantial transformation, marked by a shift from daily oral combination regimens toward long-acting injectable therapies and optimized two-drug regimens. Long-acting cabotegravir plus rilpivirine (CAB + RPV LA) has emerged as a clinically validated maintenance option, with the LATTE-2 study demonstrating durable efficacy over approximately five years: at week 256, 81% of participants in the randomized every-8-week and every-4-week groups and 93% of extension-switch participants maintained HIV-1 RNA <50 copies/mL, with no protocol-defined virologic failures after week 48. Real-world data reinforce these findings — the BEYOND study reported that 97% of participants with baseline viral load data achieved a viral load <50 copies/mL at month 12, with mean treatment satisfaction scores increasing significantly from baseline and 97% of participants preferring long-acting over oral treatment. Demonstration projects, including one at an urban safety-net clinic, have further extended the use of CAB-RPV LA to patients with viremia and adherence challenges, with 97.5% projected to achieve virologic suppression by a median of 33 weeks and a virologic failure rate of 1.5% comparable to registrational trials.
Alongside long-acting injectables, the field has seen meaningful advances in optimized oral regimens and novel agents for treatment-experienced populations. The VOGUE trial — the first randomized head-to-head comparison of the two-drug regimen dolutegravir/lamivudine (DTG/3TC) versus the three-drug regimen bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as initial therapy — demonstrated noninferiority of DTG/3TC, with HIV-1 RNA <50 copies/mL achieved in 89% and 92% of participants, respectively, at week 48 (adjusted difference, -3% [95% CI, -8%, 2%]), a median time to virologic suppression of 4.1 weeks in both groups, and no treatment-emergent resistance through week 48. For heavily treatment-experienced adults with multidrug-resistant HIV-1, two first-in-class agents have received regulatory approval: fostemsavir, an attachment inhibitor that binds HIV-1 gp120 to prevent CD4 receptor engagement, and lenacapavir, a capsid inhibitor administered subcutaneously every 26 weeks that targets nuclear entry, viral assembly, and capsid formation. In the CAPELLA study, lenacapavir plus an optimized background regimen achieved HIV-1 RNA suppression in 82% of participants after two years, with treatment-emergent capsid resistance occurring in 19% (14/72) of participants — a consequence identified as functional lenacapavir monotherapy — and seven of those participants reattaining HIV-1 RNA <50 copies/mL upon optimized background regimen resumption or change while remaining on lenacapavir.
The evolution of the treatment landscape has also been shaped by a growing understanding of long-term safety considerations and the expansion of long-acting approaches into prevention. Tenofovir disoproxil fumarate (TDF)-associated toxicities — including proximal renal tubulopathy, Fanconi syndrome, osteomalacia, and pathological fractures — have reinforced the clinical rationale for switching to tenofovir alafenamide (TAF)-based or TDF-free regimens, with a randomized controlled trial in women demonstrating that switching from TDF/FTC/NNRTI to abacavir/lamivudine/dolutegravir improved total hip BMD by a mean adjusted difference of 1% (P = 0.027) and lumbar spine BMD by 3% (P = 0.002) at week 48. Weight gain associated with integrase strand transfer inhibitor (INSTI)-based regimens has been identified as a clinically relevant concern, with INSTI regimens associated with more pronounced BMI increases than boosted protease inhibitor or NNRTI regimens, and a >10% weight gain in the first year of ART linked to increased risk of diabetes mellitus (HR 2.01, 95% CI [1.30, 3.08]) and metabolic syndrome (HR 2.24 [1.55, 2.62]). In prevention, lenacapavir has been approved for PrEP based on the PURPOSE trials, and an indirect treatment comparison estimated comparable and high efficacy between lenacapavir and cabotegravir versus no PrEP, with cabotegravir efficacy of 96% (95% CrI: 90%, 98%) in men who have sex with men and transgender women and 98% (95% CrI: 89%, 100%) in cisgender women in the HPTN trials.
A New Frontier for Long-Acting HIV Treatment in Unsuppressed Patients
The recent success of ViiV Healthcare's Cabenuva in the Phase IIIb CROWN study marks a pivotal moment for individuals living with HIV-1 who have struggled to achieve viral suppression on oral therapies. For years, long-acting injectable antiretroviral treatment (LAI-ART) has been a game-changer for those already virally suppressed, offering freedom from daily pills and improving quality of life. However, a significant unmet need has persisted for treatment-experienced patients with detectable viral loads, often due to adherence challenges or complex resistance profiles.
The CROWN study's findings, demonstrating superior viral suppression with direct initiation of Cabenuva in this unsuppressed population, directly addresses this gap. This is a critical development, building on previous research like the LATITUDE study, which showed LAI-ART's superiority in patients with adherence difficulties. For individuals who find daily pill-taking a burden or a source of stigma, a monthly or bi-monthly injection could be transformative, fostering better adherence and ultimately, better health outcomes.
However, the path forward is not without its considerations. The efficacy of rilpivirine, a component of Cabenuva, can be compromised by pre-existing resistance-associated mutations, which are more prevalent in treatment-experienced individuals. While the CROWN study was successful, careful screening for these mutations remains paramount to ensure optimal patient selection and prevent virologic failure. Furthermore, while patient satisfaction with LAI-ART is generally high, injection site reactions, though mostly mild, are common. Real-world implementation also presents logistical hurdles, including the need for robust healthcare infrastructure to manage injections, cold chain requirements, and ensuring consistent patient attendance for scheduled doses. Addressing these practical and clinical considerations will be key to maximizing the impact of this promising new treatment option for a population that urgently needs it.
Frequently Asked Questions
References
- [1] Kityo CM, Gupta SK et al.. Efficacy and safety of B/F/TAF in treatment-naïve and virologically suppressed people with HIV ≥ 50 years of age: integrated analysis from six phase 3 clinical trials. BMC infectious diseases. 2025 Aug 22. 40846915
- [2] Leonidou L, Lourida G et al.. Characteristics and management of low-level viraemia in people living with HIV in a resource-limited setting: A multicentre retrospective study in Greece. HIV medicine. 2026 Oct. 42559982
- [3] Saini S, Bhalla P et al.. Resistance-associated mutations in HIV-1 among patients failing first-line antiretroviral therapy. Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002). 2012 May-Jun. 21990611
- [4] Wijting I, Rokx C et al.. Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial. The lancet. HIV. 2017 Dec. 29107562
- [5] Marcelin AG, Soulie C et al.. Emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second-generation InSTIs in two- and three-drug regimens: the Virostar-1 study. The Journal of antimicrobial chemotherapy. 2025 Jan 3. 39436753
- [6] Endo T, Tazawa Y et al.. Perioperative pharmacokinetics of lenacapavir during massive hemorrhage in a patient with hemophilia a undergoing liver transplantation. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2026 Jun. 42048836
- [7] Bares SH, Wu X et al.. Weight Gain After Antiretroviral Therapy Initiation and Subsequent Risk of Metabolic and Cardiovascular Disease. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2024 Feb 17. 37698083
- [8] Psaros C, Goodman GR et al.. HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study. Journal of the International AIDS Society. 2024 May. 38783534
- [9] Neverette NC, Dumond JB et al.. Lenacapavir: Playing the Long Game in the New Era of Antiretrovirals. Clinical pharmacology and therapeutics. 2025 Feb. 39323028
- [10] Daar ES, DeJesus E et al.. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. The lancet. HIV. 2018 Jul. 29925490
- [11] Kityo C, Mambule IK et al.. Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial. The Lancet. Infectious diseases. 2024 Oct. 38821073
- [12] Hawkins N, Hazra A et al.. Indirect Treatment Comparison of the Efficacy of Long-Acting Injectable Cabotegravir Compared With Lenacapavir for HIV Pre-exposure Prophylaxis. Advances in therapy. 2026 Aug. 42171901
- [13] Pennetzdorfer N, Naik V et al.. Week 96 resistance analysis in participants receiving bictegravir/lenacapavir in the phase 2 ARTISTRY-1 study. Antiviral therapy. 2026 Aug. 42627157
- [14] Salata RA, Grinsztejn B et al.. Predictors of virologic outcome among people living with HIV who continue a protease inhibitor-based antiretroviral regimen following virologic failure with no or limited resistance. AIDS research and therapy. 2023 Jan 5. 36604746
- [15] Naidoo KK, Highton AJ et al.. Early Initiation of Antiretroviral Therapy Preserves the Metabolic Function of CD4+ T Cells in Subtype C Human Immunodeficiency Virus 1 Infection. The Journal of infectious diseases. 2024 Mar 14. 37804102
- [16] Martini S, Salmoni L et al.. Switch from Ibalizumab to Lenacapavir in a Rescue Regimen for a Heavily Treatment-Experienced (HTE) Patient with Multidrug-Resistant (MDR) HIV-1 Infection. International journal of molecular sciences. 2025 Sep 12. 41009449
- [17] Tsai MS, Sun HY et al.. Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2023 Jan. 36384186
- [18] Lee NE, Sutherland RK. Lenacapavir and the novel HIV-1 capsid inhibitors: an emerging therapy in the management of multidrug-resistant HIV-1 virus. Current opinion in infectious diseases. 2023 Feb 1. 36753704
- [19] Raheem IT, Girijavallabhan V et al.. MK-8527 is a novel inhibitor of HIV-1 reverse transcriptase translocation with potential for extended-duration dosing. PLoS biology. 2025 Aug. 40857265
- [20] Croner AFT, Leite DI et al.. Comparative Effectiveness of Daily Oral and Long-acting Injectable Prep: A Critical Review of Clinical Evidence and Public Health Implications. Current HIV research. 2026. 41589497
Contact Us
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
For General Inquiry
info@pienomial.com
